Article and Video CATEGORIES

Cancer Journey

Search By

Understanding how tumors respond to radiation has been a lifelong process for Puneeth Iyengar, M.D., Ph.D., Assistant Professor of Radiation Oncology at UT Southwestern Medical Center. He began testing theories in school science fairs as an adolescent growing up in Louisiana. Studying at MIT furthered his interest in the biologic and engineering aspects of medicine, and he earned a bachelor of science degree in biology before receiving his M.D./Ph.D. degrees from Albert Einstein College of Medicine in New York in 2005.

Lung Cancer Onctalk 2023 - Dr. Puneeth Iyengar
A recorded live event where a team of top oncologists discusses emerging concepts and best practices in non-small cell lung cancer (NSCLC).
Author
Puneeth Iyengar, M.D., Ph.D., GRACE Faculty
Image
Lung Cancer OncTalk 2023

At our live event, Lung Cancer OncTalk 2023, Dr. Puneeth Iyengar discusses using radiation therapy in metastatic lung cancer, advances in Oligometastatic disease, (SBRT) for Oligoprogressive, The NRG-LU Trial, and future goals of metastatic NSCLC Treatment. 

To watch the complete playlist click here.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Article
Las biopsias líquidas están revolucionando la forma en que combatimos el cáncer, ofreciendo un futuro donde la detección y el tratamiento son más rápidos, precisos y menos invasivos.
Image
Videoteca de Cáncer de Pulmon - 2025
Video
Como parte de la Videoteca de Cáncer de Pulmón en Español 2025, oncólogos expertos discuten las opciones de tratamiento y la información más emergente en cáncer de pulmón. El Dr. Raez aborda la terapia para cánceres de pulmón EGFR y ALK, además de analizar otros tres temas de actualidad. La Dra. Viola y la Dra. Riaño también contribuyen a esta videoteca, cada una presentando tres temas relevantes sobre el cáncer de pulmón.
Article
The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.